Reuters -- A U.S. advisory panel on Tuesday rejected a Debiovision Inc drug after members said the company lacked enough evidence to show it was effective for treating a dangerous type of bleeding in the esophagus.
Reuters -- A U.S. advisory panel on Tuesday rejected a Debiovision Inc drug after members said the company lacked enough evidence to show it was effective for treating a dangerous type of bleeding in the esophagus.
